Duchenne Muscular Dystrophy Approval Race: BioMarin Pulls Back Into Lead
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee reviews for BioMarin’s drisapersen and Sarepta’s eteplirsen, once eyed as back-to-back meetings, are now set months apart. Draft guidance may help firms overcome previous findings of inadequate data.
You may also be interested in...
DMD Development Landscape Shifts After Prosensa Failure; Sarepta Continues Strong
The race to get a Duchenne muscular dystrophy drug to market has been closely watched by investors; new developments in drugs by Prosensa and Sarepta have created an unexpected change in the landscape of treatment development.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.